Affluent Medical SAS (AFME) - Total Assets
Based on the latest financial reports, Affluent Medical SAS (AFME) holds total assets worth €59.84 Million EUR (≈ $69.96 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AFME equity to assets ratio to measure how much of total assets are equity-financed.
Affluent Medical SAS - Total Assets Trend (2016–2024)
This chart illustrates how Affluent Medical SAS's total assets have evolved over time, based on quarterly financial data. Check AFME goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Affluent Medical SAS - Asset Composition Analysis
Current Asset Composition (December 2024)
Affluent Medical SAS's total assets of €59.84 Million consist of 20.0% current assets and 80.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.23 Million | 2.0% |
| Accounts Receivable | €3.45 Million | 5.7% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €1.25 Million | 2.1% |
| Intangible Assets | €15.14 Million | 24.9% |
| Goodwill | €32.20 Million | 52.9% |
Asset Composition Trend (2016–2024)
This chart illustrates how Affluent Medical SAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Affluent Medical SAS (AFME) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Affluent Medical SAS's current assets represent 20.0% of total assets in 2024, an increase from 6.3% in 2016.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2024, down from 2.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 76.0% of total assets, a decrease from 93.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 52.9% of total assets.
Affluent Medical SAS Competitors by Total Assets
Key competitors of Affluent Medical SAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
|
China | CN¥3.54 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
Affluent Medical SAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 0.45 | 2.69 |
| Quick Ratio | 1.07 | 0.37 | 2.51 |
| Cash Ratio | 0.00 | 0.06 | 0.00 |
| Working Capital | €805.00K | €-7.93 Million | €4.22 Million |
Affluent Medical SAS - Advanced Valuation Insights
This section examines the relationship between Affluent Medical SAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.41 |
| Latest Market Cap to Assets Ratio | 1.81 |
| Asset Growth Rate (YoY) | 7.5% |
| Total Assets | €60.86 Million |
| Market Capitalization | $110.43 Million USD |
Valuation Analysis
Above Book Valuation: The market values Affluent Medical SAS's assets above their book value (1.81x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Affluent Medical SAS's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Affluent Medical SAS (2016–2024)
The table below shows the annual total assets of Affluent Medical SAS from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €60.86 Million ≈ $71.15 Million |
+7.48% |
| 2023-12-31 | €56.62 Million ≈ $66.20 Million |
-5.66% |
| 2022-12-31 | €60.02 Million ≈ $70.17 Million |
-14.30% |
| 2021-12-31 | €70.03 Million ≈ $81.88 Million |
+8.04% |
| 2020-12-31 | €64.83 Million ≈ $75.79 Million |
-0.65% |
| 2019-12-31 | €65.25 Million ≈ $76.29 Million |
-3.18% |
| 2017-12-31 | €67.39 Million ≈ $78.79 Million |
+9.19% |
| 2016-12-31 | €61.72 Million ≈ $72.16 Million |
-- |
About Affluent Medical SAS
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more